secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2022-03-23T23:59:59+00:00
Accession:  0000950170-22-004419
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences reports FY2021 net loss $35.3M; cash $149.1M into 2024
-----------------------------------------------------------------------

- Net loss for FY2021 was $35.3M, up from $22.2M in FY2020; R&D expenses rose to $25.2M.
- Cash and equivalents totaled $149.1M at Dec 31, 2021; runway into 2024.
- On track to initiate pivotal trial in choroidal melanoma and Phase 1 in NMIBC in 2H 2022.
- European Commission granted Orphan Drug Designation for AU-011 in uveal melanoma.
- John Maraganore, former Alnylam CEO, joins as strategic advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017022004419/0000950170-22-004419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017022004419/aura-20220323.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-004419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer